Endothelin-receptor interactions. Role of a putative sulfhydryl on the endothelin receptor

Topographical distribution of neurons containing endothelin type A receptor in the rat brain

Endothelin (ET) was originally identified as a vasoactive peptide biosynthesized in vascular endothelial cells. Because ET has also been found in the brain as a neuropeptide, it has been thought to belong to the group of brain-vascular peptide hormones. To date, type A and type B receptors for ET have been found. To elucidate the topographic distribution of type A receptor (ET-AR) in the brain, we raised a specific antibody to the C-terminal (64 amino acids) peptide of rat ET-AR and immunostained rat brain sections with this antibody. Immunoreactivity for ET-AR was detected in neuronal cell bodies and also in the many proximal and some distal parts of their fibers. Nerve cell bodies containing strong ET-AR-immunoreactivity were distributed in the lateral part of the reticular formation, the nucleus of the solitary tract and its surrounding area, the dorsal midline area and medial longitudinal fasciculus, the subependymal layer of the fourth ventricular roof, the caudolateral area of the pontine tegmentum, the locus coeruleus, the rostral pontine area of the lateral reticular formation, the retrorubral area, the substantia nigra, the ventral tegmental area, the periventricular region lateral to the rostral mesencephalic aqueduct and caudal third ventricle, the arcuate hypothalamic nucleus, the caudomedial area of the zona incerta, the periventricular hypothalamic nucleus, the parvocellular portion of the paraventricular hypothalamic nucleus, and the periglomerular region of the olfactory bulb. In addition, the Purkinje cells of the cerebellar cortex, the nerve cells in the mesencephalic trigeminal nucleus, and the magnocellular neurons of the supraoptic and paraventricular hypothalamic nuclei showed weak immunoreactivity. The distribution of highly ET-AR-immunoreactive neurons is quite similar to that ofcatecholamine neurons.

Thrombin-induced vascular reactivity is modulated by ETB receptor-coupled nitric oxide release in rat aorta

The role of endothelin (ET) receptors in thrombin-induced modulation of vascular tone was evaluated by direct measurement of ET-1 and ET receptor-coupled nitric oxide (NO) release and developed isometric tension in thrombin-treated aortic rings. Here we report that rapid release of ET-1 and subsequent ETB receptor activation are required for production of the potent vasodilator NO by thrombin-stimulated aorta. Thrombin-induced NO release is ablated by pretreatment with ETB receptor antagonists or after ET receptor desensitization by repeated stimulation with ET-1. Thrombin-induced relaxation of precontracted vessels was abrogated in the presence of ETB receptor antagonists and, in contrast, marked contraction to thrombin was observed. These data indicate that the endothelium-dependent vasodilator activity previously attributed to thrombin is indirect and requires ETB receptor-coupled NO release and suggest that ET receptor modulation of thrombin-induced vascular tone may contribute to the increased vasomotor tone observed in diseased and mechanically injured vessels.

Human astrocytoma U138MG cells express predominantly type-A endothelin receptor

Endothelin-1 (ET-1) binding to human astrocytoma U138MG cells was time-dependent, and bound [125I]ET-1 was difficult to dissociate. The B(max) and Kd values of [125I]ET-1 binding were 70 fmol/mg and 0.07 nM, respectively. Interestingly, different from other astrocytoma cells and astrocytes, the U138MG cells expressed predominantly ETA receptor as shown by RT-PCR results and binding studies. ET-1, FR139317, BQ123, PD142893 and Ro46-2005 inhibited specific [125I]ET-1 binding with Ki values of 0.10, 0.53, 4.3, 22, and 320 nM, respectively. ETB selective ligands ET-3 and IRL1620 were much less potent. The inhibitory effects of antagonists BQ123 and PD142893 on [125I]ET-1 binding diminished following the incubation time. ET-1 binding caused a modest stimulation in phosphatidylinositol hydrolysis with an EC50 value of 24 nM. In comparison to the human U373MG cells, ET-1-induced receptor internalization in U138MG cells was less efficient with 42% of bound ET-1 internalized after 30 min of incubation. These results imply that human astrocytoma cells/astrocytes are able to express either ETA or ETB receptor under different pathophysiological conditions.

The development of potent peptide agonists and antagonists for the endothelin receptors

The endothelins (ETs), sarafotoxins (SRTXs), vasoactive intestinal contractor (VIC), and bibrotoxin are a family of potent vasoconstrictor peptides. All peptides in this family possess 21 amino acids arranged in a unique bicyclic motif formed between cystine bridges in the 1-15 and 3-11 positions. Since the discovery of endothelin-1 (ET-1) in 1988, significant effort has been focused on the understanding of its structure-activity relationships. The identification of endothelin receptor subtypes has led to the discovery/design of potent peptide agonists and antagonists, along with nonpeptide antagonists of endothelin with varying levels of potency and receptor subtype selectivity. In keeping with the theme of this journal, this review will focus only on the development of peptidic-based agonists and antagonists of endothelin in addition to their applications in understanding the physiological and/or pathophysiological role of endothelin and its isopeptides.